Towards Healthcare Research & Consulting

Multispecific Antibodies Top Companies and Strategic Involvements

Date : 24 April 2026

Who are the Multispecific Antibodies Market Top Companies and What are Their Offerings?

Multispecific Antibodies Market Companies are Roche, Johnson & Johnson, Amgen, Abbive, Pfizer, Regeneron, Genmab, Zymeworks

Companies Headquarters Multispecific Antibodies
Roche Basel, Switzerland Hemlibra, Columvi, Lunsumio, and Vabysmo
Johnson & Johnson New Brunswick, U.S. Rybrevant, Talvey, and Tecvayli
Amgen Thousand Oaks, U.S. Blincyto and Imdelltra
Abbive North Chicago, U.S. Epkinly
Pfizer New York, U.S. Elrexfio
Regeneron Tarrytown, U.S. Ordspono and Linvoseltamab
Genmab Copenhagen, Denmark Epkinly and Rybrevant
Zymeworks Vancouver, Canada Ziihera
Akeso Biopharma Zhongshan, China Kaitanni and Yi-da-fang
Immunocore Abingdon, UK Kimmtrak

Recent Developments in the Multispecific Antibodies Market

  • In April 2026, dosing of the first participant in the Phase 1 clinical trial of MDX2301, which is a tetravalent bispecific antibody neutralizing all known variants of SARS-CoV-2, was announced by ModeX Therapeutics Inc. The product is a single molecule with the combination of multiple antibody binding domains, promoting the prevention of COVID-19.
  • In February 2026, the IND application for initiation of CS2009 phase II clinical trial was announced by CStone Pharmaceuticals (CStone). CS2009 is an innovative trispecific antibody combining 3 clinically validated targets: CTLA-4, PD-1, and VEGFA, offering synergistic actions and multidimensional anti-tumour effects, driving their use against advanced solid tumours.

Multispecific Antibodies Market Value Chain Analysis

R&D

  • The R&D of the multispecific antibodies focuses on the development of next-generation trispecific and T-cell engager platforms.
  • Key players: Johnson & Johnson, Roche, Amgen.

Clinical Trials and Regulatory Approvals

  • The safety, immunogenicity, efficacy, pharmacokinetics, and pharmacodynamics are evaluated in the clinical trials and regulatory approvals of multispecific antibodies.
  • Key players: Johnson & Johnson, Amgen, Regeneron.

Patient Support and Services

  • The educational resources, personalized one-on-one care navigation, and financial assistance are provided in the patient support and services of the multispecific antibodies.
  • Key players: Johnson & Johnson, Roche, Amgen.

Market Growth

The global multispecific antibodies market size was estimated at USD 7.56 billion in 2025 and is predicted to increase from USD 8.66 billion in 2026 to approximately USD 29.28 billion by 2035, expanding at a CAGR of 14.5% from 2026 to 2035. The expanding application of multispecific antibodies is increasing their use. Growing R&D activities, healthcare investments, technological advancements, and new product launches are also enhancing the market growth.

Multispecific Antibodies Market Size is USD 8.66 Billion in 2026.